- Home
- FMY vs CTSO Comparison
FMY vs CTSO Comparison
Compare FMY & CTSO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMY
- CTSO
- Stock Information
- Founded
- FMY 2005
- CTSO 1997
- Country
- FMY United States
- CTSO United States
- Employees
- FMY N/A
- CTSO N/A
- Industry
- FMY Finance/Investors Services
- CTSO Medical/Dental Instruments
- Sector
- FMY Finance
- CTSO Health Care
- Exchange
- FMY Nasdaq
- CTSO Nasdaq
- Market Cap
- FMY 51.0M
- CTSO 45.3M
- IPO Year
- FMY N/A
- CTSO N/A
- Fundamental
- Price
- FMY $11.98
- CTSO $0.63
- Analyst Decision
- FMY
- CTSO Buy
- Analyst Count
- FMY 0
- CTSO 2
- Target Price
- FMY N/A
- CTSO $5.38
- AVG Volume (30 Days)
- FMY 10.1K
- CTSO 114.8K
- Earning Date
- FMY 01-01-0001
- CTSO 11-13-2025
- Dividend Yield
- FMY 6.98%
- CTSO N/A
- EPS Growth
- FMY N/A
- CTSO N/A
- EPS
- FMY N/A
- CTSO N/A
- Revenue
- FMY N/A
- CTSO $36,979,520.00
- Revenue This Year
- FMY N/A
- CTSO $11.93
- Revenue Next Year
- FMY N/A
- CTSO $21.22
- P/E Ratio
- FMY N/A
- CTSO N/A
- Revenue Growth
- FMY N/A
- CTSO 20.75
- 52 Week Low
- FMY $10.71
- CTSO $0.60
- 52 Week High
- FMY $12.17
- CTSO $1.61
- Technical
- Relative Strength Index (RSI)
- FMY 43.08
- CTSO 28.37
- Support Level
- FMY $11.96
- CTSO $0.61
- Resistance Level
- FMY $12.06
- CTSO $0.70
- Average True Range (ATR)
- FMY 0.11
- CTSO 0.06
- MACD
- FMY -0.00
- CTSO -0.00
- Stochastic Oscillator
- FMY 39.69
- CTSO 14.29
About FMY First Trust Motgage Income Fund of Beneficial Interest
First Trust Mortgage Income Fund is a United States based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield and maturity.
About CTSO Cytosorbents Corporation
CytoSorbents Corp specializes in treating life-threatening conditions in intensive care and cardiac surgery using proprietary polymer adsorption technology. Its flagship product, CytoSorb, is approved in the EU as an extracorporeal cytokine absorber, aiming to reduce inflammation and prevent multiple organ failure in critical illnesses like sepsis and trauma. Revenue primarily comes from product sales in Germany, with additional income from grant agencies in the United States. The company operates through Direct sales and Distributors/strategic partners in United States, Germany and Other Countries. The company's product consists of Cytosorb, ECOS-300CY, VetResQ, HemoDefend, and DrugSorb-ATR.